ERBB2 S310F

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma2
ERBB2 S310F	Chemotherapy	Predictive	C	Supports Sensitivity Response	3	submitted	EID11496 Variant found in patient's that were diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID: 9013, CF0943, CF0945, CF1005, CF0955). Th… (full text at CIViC) PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC	civic
ERBB2 S310F AND NOT ERBB2 T306M	Chemotherapy	Predictive	C	Supports Sensitivity Response	3	submitted	EID11497 Variants were found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID: 9013). The patient was categorised a… (full text at CIViC) PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Bladder Carcinoma2

ERBB2 S310F

Chemotherapy

Predictive

Supports Sensitivity Response

submitted

EID11496

Variant found in patient's that were diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID: 9013, CF0943, CF0945, CF1005, CF0955). Th… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

civic

ERBB2 S310F AND NOT ERBB2 T306M

Chemotherapy

Predictive

Supports Sensitivity Response

submitted

EID11497

Variants were found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID: 9013). The patient was categorised a… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Bladder Urothelial Carcinoma2
ERBB2 S310F	(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID11364 Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (DSH1 and 5637). The variant is located in the Extracellular II domain. RT112 cells infected with lentiviral vec… (full text at CIViC) PMID 24971884 · de Martino et al., 2014 · Open in CIViC	civic
ERBB2 S310F	Lapatinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID11365 Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell lines (DSH1 and 5637). The variant is located in the Extracellular II domain. In regards to the response to lapatinib… (full text at CIViC) PMID 24971884 · de Martino et al., 2014 · Open in CIViC	civic

Bladder Urothelial Carcinoma2

ERBB2 S310F

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID11364

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (DSH1 and 5637). The variant is located in the Extracellular II domain. RT112 cells infected with lentiviral vec… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

civic

ERBB2 S310F

Lapatinib

Predictive

Supports Sensitivity Response

submitted

EID11365

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell lines (DSH1 and 5637). The variant is located in the Extracellular II domain. In regards to the response to lapatinib… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

civic

Carcinoma1
ERBB2 S310F	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	submitted	EID11493 Cell proliferation analysis of NIH 3T3 cells harboring the S310F variation exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A kinase-inacti… (full text at CIViC) PMID 22908275 · Greulich et al., 2012 · Open in CIViC	civic

Carcinoma1

ERBB2 S310F

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID11493

Cell proliferation analysis of NIH 3T3 cells harboring the S310F variation exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A kinase-inacti… (full text at CIViC)

PMID 22908275 · Greulich et al., 2012 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma3
ERBB2 Amplification OR ERBB2 A775_G776insIVMA OR ERBB2 A775_G776insYVMA OR ERBB2 G778_P780dup OR ERBB2 G778-779 insCPG OR ERBB2 G776_V777>VCV OR ERBB2 G776delinsVC OR ERBB2 L755P OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 S335C	Ado-trastuzumab Emtansine Regimen	Predictive	B	Supports Sensitivity Response	3	submitted	EID11323 In this phase II basket trial, 18 patients with advanced HER2-mutant lung adenocarcinomas were enrolled to receive ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression.… (full text at CIViC) PMID 29989854 · Li et al., 2018 · Open in CIViC	civic
ERBB2 S310F	Trastuzumab Deruxtecan	Predictive	A	Supports Sensitivity Response	3	accepted	EID11751 In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC	civic
ERBB2 Y772_A775dup OR ERBB2 G778_P780dup OR ERBB2 G776delinsVC OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 G776delinsLC	Sevabertinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID12807 In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC) PMID 41104928 · Le et al., 2025 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma3

ERBB2 Amplification OR ERBB2 A775_G776insIVMA OR ERBB2 A775_G776insYVMA OR ERBB2 G778_P780dup OR ERBB2 G778-779 insCPG OR ERBB2 G776_V777>VCV OR ERBB2 G776delinsVC OR ERBB2 L755P OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 S335C

Ado-trastuzumab Emtansine Regimen

Predictive

Supports Sensitivity Response

submitted

EID11323

In this phase II basket trial, 18 patients with advanced HER2-mutant lung adenocarcinomas were enrolled to receive ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression.… (full text at CIViC)

PMID 29989854 · Li et al., 2018 · Open in CIViC

civic

ERBB2 S310F

Trastuzumab Deruxtecan

Predictive

Supports Sensitivity Response

accepted

EID11751

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

civic

ERBB2 Y772_A775dup OR ERBB2 G778_P780dup OR ERBB2 G776delinsVC OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 G776delinsLC

Sevabertinib

Predictive

Supports Sensitivity Response

accepted

EID12807

In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC)

PMID 41104928 · Le et al., 2025 · Open in CIViC

civic

Malignant Breast Neoplasm1
ERBB2 S310F	Afatinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID11691 In this phase II NCI-MATCH trial, a patient with ER+ lobular breast cancer with ERBB2 S310F mutation was treated with afatinib. A 51% reduction of RECIST target lesions was reported after six cycles, … (full text at CIViC) PMID 35939768 · Bedard et al., 2022 · Open in CIViC	civic

Malignant Breast Neoplasm1

ERBB2 S310F

Afatinib

Predictive

Supports Sensitivity Response

accepted

EID11691

In this phase II NCI-MATCH trial, a patient with ER+ lobular breast cancer with ERBB2 S310F mutation was treated with afatinib. A 51% reduction of RECIST target lesions was reported after six cycles, … (full text at CIViC)

PMID 35939768 · Bedard et al., 2022 · Open in CIViC

civic

Pancreatic Ductal Adenocarcinoma2
ERBB2 S310F	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11547 HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
KRAS G12D AND ERBB2 S310F	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11548 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic

Pancreatic Ductal Adenocarcinoma2

ERBB2 S310F

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID11547

HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

civic

KRAS G12D AND ERBB2 S310F

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID11548

KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC)

PMID 31046123 · Li et al., 2020 · Open in CIViC

civic

Unmapped disease1unmapped disease
ERBB2 S310F	(functional)	Functional	D	Supports Gain Of Function	4	submitted	EID11492 The ERBB2 protein with the S310F variant exhibits high C-terminal hyperphosphorylation and increased proteins with phosphorylated peptides in the downstream pathway. PMID 22908275 · Greulich et al., 2012 · Open in CIViC	civic

Unmapped disease1unmapped disease

ERBB2 S310F

(functional)

Functional

Supports Gain Of Function

submitted

EID11492

The ERBB2 protein with the S310F variant exhibits high C-terminal hyperphosphorylation and increased proteins with phosphorylated peptides in the downstream pathway.

PMID 22908275 · Greulich et al., 2012 · Open in CIViC

civic

Evidence by cancer (12 items)

Clinical significance (0)